Endocrine Abstracts

Background: Hypertension (HTN) is the most frequent adverse event during treatment with Lenvatinib (LEN) for advanced Radioactive Iodine-Resistant Thyroid Cancer (RAI-R TC), but data on its best therapeutic management are limited.Objectives: To assess incidence, features and best management of LEN-related HTN in a consecutive single tertiary-care Centre.Methods: Evaluation included 29 patients treated with LEN, followed for a mean ...